What is CureDuchenne?
CureDuchenne operates under a unique venture philanthropy framework, channeling financial backing into cutting-edge research, early diagnostic initiatives, and enhanced treatment accessibility for Duchenne muscular dystrophy. The organization serves as a vital resource, connecting families with leading scientists, physical therapists, and fundraising experts. Through its dedicated efforts, CureDuchenne has amassed over $50 million for research and care, catalyzing advancements in clinical trials and contributing to the development of FDA-approved therapies for DMD. This strategic approach to funding research and care positions CureDuchenne at the forefront of the fight against this debilitating genetic disorder.
How much funding has CureDuchenne raised?
CureDuchenne has raised a total of $785K across 2 funding rounds:
Debt
$350K
Debt
$435K
Debt (2020): $350K with participation from PPP
Debt (2021): $435K led by PPP
What's next for CureDuchenne?
With the recent influx of major strategic investment, CureDuchenne is poised to further amplify its impact on the DMD landscape. The organization's venture philanthropy model is expected to drive accelerated progress in critical research areas and expand its support programs for affected families. This substantial backing will likely enable CureDuchenne to deepen its engagement with scientific collaborators, enhance its diagnostic resources, and potentially influence the trajectory of new treatment development. The sustained commitment of capital indicates a strong belief in CureDuchenne's mission and its capacity to achieve significant milestones in the ongoing quest for a cure.
See full CureDuchenne company page
